Liminal BioSciences Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Liminal BioSciences are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Liminal BioSciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite quite persistent basic indicators, Liminal BioSciences is not utilizing all of its potentials. The recent stock price mess, may contribute to short-term losses for the institutional investors. ...more
Liminal |
Liminal BioSciences Relative Risk vs. Return Landscape
If you would invest (100.00) in Liminal BioSciences on October 17, 2025 and sell it today you would earn a total of 100.00 from holding Liminal BioSciences or generate -100.0% return on investment over 90 days. Liminal BioSciences is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Liminal, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Liminal BioSciences Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Liminal BioSciences' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Liminal BioSciences, and traders can use it to determine the average amount a Liminal BioSciences' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| LMNL |
Based on monthly moving average Liminal BioSciences is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Liminal BioSciences by adding Liminal BioSciences to a well-diversified portfolio.
Liminal BioSciences Fundamentals Growth
Liminal Stock prices reflect investors' perceptions of the future prospects and financial health of Liminal BioSciences, and Liminal BioSciences fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Liminal Stock performance.
| Return On Equity | -1.42 | |||
| Return On Asset | -0.39 | |||
| Profit Margin | 2.67 % | |||
| Operating Margin | (65.03) % | |||
| Current Valuation | 9.32 M | |||
| Shares Outstanding | 3.25 M | |||
| Price To Earning | 0.92 X | |||
| Price To Book | 0.44 X | |||
| Price To Sales | 32.76 X | |||
| Revenue | 401 K | |||
| EBITDA | (31.86 M) | |||
| Cash And Equivalents | 55.8 M | |||
| Cash Per Share | 1.80 X | |||
| Total Debt | 1.49 M | |||
| Debt To Equity | 1.31 % | |||
| Book Value Per Share | 6.61 X | |||
| Cash Flow From Operations | (31.82 M) | |||
| Earnings Per Share | (6.80) X | |||
| Total Asset | 50.46 M | |||
| Retained Earnings | (1.08 B) | |||
| Current Asset | 88.51 M | |||
| Current Liabilities | 30.36 M | |||
Things to note about Liminal BioSciences performance evaluation
Checking the ongoing alerts about Liminal BioSciences for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Liminal BioSciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Liminal BioSciences is not yet fully synchronised with the market data | |
| Liminal BioSciences has some characteristics of a very speculative penny stock | |
| Liminal BioSciences has a very high chance of going through financial distress in the upcoming years | |
| Liminal BioSciences currently holds about 55.8 M in cash with (31.82 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.8. | |
| Roughly 61.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Liminal BioSciences' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Liminal BioSciences' stock is overvalued or undervalued compared to its peers.
- Examining Liminal BioSciences' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Liminal BioSciences' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Liminal BioSciences' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Liminal BioSciences' stock. These opinions can provide insight into Liminal BioSciences' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Other Consideration for investing in Liminal Stock
If you are still planning to invest in Liminal BioSciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Liminal BioSciences' history and understand the potential risks before investing.
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |